Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $127.71

Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus rating of “Buy” from the nine analysts that are presently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $147.50.

A number of research analysts have issued reports on PCVX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Guggenheim reissued a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total value of $1,386,750.00. Following the sale, the chief executive officer now owns 450,301 shares of the company’s stock, valued at $41,630,327.45. The trade was a 3.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 76,616 shares of company stock worth $6,766,481. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Whipplewood Advisors LLC bought a new position in Vaxcyte in the 4th quarter worth approximately $28,000. Blue Trust Inc. raised its position in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the period. Smartleaf Asset Management LLC grew its holdings in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares during the last quarter. National Bank of Canada FI purchased a new position in shares of Vaxcyte during the fourth quarter valued at about $41,000. Finally, Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after buying an additional 635 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 5.6 %

NASDAQ:PCVX opened at $74.22 on Tuesday. The business’s 50 day moving average is $84.86 and its two-hundred day moving average is $94.74. Vaxcyte has a 52 week low of $58.10 and a 52 week high of $121.06. The company has a market cap of $9.25 billion, a PE ratio of -16.13 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. As a group, sell-side analysts expect that Vaxcyte will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.